UK – Brainomix’s AI-enabled stroke software endorsed by NICE

The National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix’s artificial intelligence (AI)-enabled software, Brainomix 360, to...
MHRA Offers Grace Period for Device Manufacturers Dealing With Withdrawn Notified Bodies

UK – Illegal medicines worth more than £30 million seized in the UK in...

This includes more than two million doses seized during Operation Pangea, the international initiative of global enforcement partners that targets the illegal internet trade in medical...
NICE grants Lynparza expansion for advanced ovarian cancer

UK – Updated NICE guidance recommends more targeting of antibiotics to those at the...

NICE has today (Wednesday, 31 January) recommended better targeting of antibiotics for suspected sepsis to ensure the right people receive treatment as soon as...

Europe – EMA proposes waiving comparative efficacy studies for certain biosimilars

The European Medicines Agency (EMA) is proposing to waive comparative efficacy studies (CES) for biosimilars with a straightforward mechanism of action (MOA), such as...

Europe – Products Management Services (PMS) – Implementation of International Organization for Standardization (ISO)...

The EMA intends to migrate the Centrally Authorised Products (CAPs) and non-Centrally Authorised Products (non-CAPs) data held in the eXtended Eudravigilance Medicinal Product Dictionary...
NICE grants Lynparza expansion for advanced ovarian cancer

UK – Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

The CD19-directed antibody-drug conjugate (ADC) has specifically been recommended for use in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade...

Europe – Clinical trials’ transition to new EU system – one year left

All ongoing clinical trials in the EU must be transitioned to the Clinical Trials Information System (CTIS) by 31 January 2025. This date marks...

Europe – Experts outline challenges of combination products in Europe

Combination products are increasingly important, increasingly complex and are increasing the pressure on the European regulatory network, according to Thomas Wejs Møller, senior director...

Europe – Precautionary measures to address potential risk of neurodevelopmental disorders in children born...

On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These measures...

Europe – Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)...

Three new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting. The committee recommended granting a marketing...

NOS PROCHAINES FORMATIONS